Incyte reported promising results from a Phase 2 of using Opzelura cream in adult patients with mild-to-moderate hidradenitis suppurativa (HS).
Results were announced at the American Academy of Dermatology Annual Meeting.
The study demonstrated a significantly greater reduction in abscess and inflammatory nodule count in patients treated with the cream.
The study results showed that ruxolitinib cream 1.5% was generally well-tolerated.
“HS is a chronic, debilitating skin condition that unfortunately has no cure, so managing the signs and symptoms through an effective treatment is key to ensuring patients are able to live their lives with minimal impact from this disease,” said Dr. Martina J. Porter, Beth Israel Deaconess Medical Center. “Better disease control can help manage the persistent symptoms of HS for these patients. There still remains a very large need for effective therapies for patients with HS, particularly for those with milder HS, and I’m encouraged by the results from this Phase 2 study of ruxolitinib cream for this patient population.”
Opzelura, a ream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo (loss of skin pigment) in patients 12 years of age and older.
Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in some patients.
Incyte is based near Wilmington and has nearly 1,500 employees in the area.
Opznelura accounts for about $338 million of Incyte’s $4 billion in annual sales.
